"Team Science in Gastrointestinal Oncology"

Speaker:

Dung Le, M.D.
Bloomberg-Kimmel Professor of Cancer Immunotherapy
Division of Gastrointestinal Malignancies
Department of Medical Oncology
Johns Hopkins University

About Dung Le:

Dr. Le holds a bachelor's degree from Yale University and earned her medical degree at Johns Hopkins University, where she then completed internal medicine residency training followed by a fellowship in oncology.

Her research interests include novel approaches to patients with gastrointestinal malignancies. She has served as the principal investigator (PI) on many clinical trials focused on testing immunotherapy in patients with gastrointestinal malignancies and she has also served as the national PI on several studies including: anti-programmed death-1 (PD-1) in tumors with mismatch repair deficiency; a clinical trial in advanced pancreatic cancer patients evaluating the safety, tolerability and immune response to CRS-207, a listeria vaccine platform which has been modified to express the tumor antigen mesothelin; a multi-center, phase 2 study testing CRS-207 as a boost to allogenic pancreatic tumor cells transfected with GM-CSF gene (GVAX) for treatment of advanced pancreatic adenocarcinoma (PDA); a trial testing GVAX/ipilimumab in the maintenance setting for metastatic pancreatic cancer; and GVAX/CRS-207 +/- nivolumab in metastatic pancreatic cancer.

These studies incorporate extensive laboratory correlates and have involved collaborations with clinicians and bench scientists with expertise in the fields of immunotherapy and cancer genomics.